Table 1.
Patient Baseline Characteristics: Life Goals Collaborative Care (LGCC) Vs. Enhanced Treatment as Usual
| Total (N= 65) |
LGCC (N=32) |
Enhanced Treatment as Usual (N=33) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Demographics | Mean±SD | Mean±SD | Mean±SD | T | df | p | |||
| Age M ± SD | 45.3±12.8 | 47.2±11.8 | 43.4±13.6 | −1.20 | 63 | .24 | |||
| N | % | N | % | N | % | Chi-sq | p | ||
| Female | 39 | 61 | 18 | 56 | 21 | 66 | .59 | 1 | .44 |
| African-American | 12 | 19 | 7 | 22 | 5 | 16 | .34 | 1 | .56 |
| Some college education | 41 | 64 | 22 | 71 | 19 | 58 | 1.25 | 1 | .26 |
| Current Illicit Substance Use | 17 | 27 | 8 | 27 | 9 | 28 | .02 | 1 | .90 |
| Current smoker | 33 | 54 | 15 | 50 | 18 | 58 | .40 | 1 | .53 |
| Medication and Health Services Use | N | % | N | % | N | % | Chi-sq | p | |
| Any mood stabilizer prescriptiona | 17 | 26 | 10 | 31 | 7 | 21 | .85 | 1 | .36 |
| Any atypical antipsychotic prescriptiona | 7 | 11 | 3 | 9 | 4 | 12 | .13 | 1 | .72 |
| Insurance type | |||||||||
| Medicaid | 13 | 28 | 8 | 33 | 5 | 22 | 7.67 | 3 | .06 |
| Medicare | 12 | 26 | 6 | 25 | 6 | 26 | |||
| Medicaid&Medicare | 16 | 34 | 10 | 42 | 6 | 26 | |||
| Other insurance | 6 | 13 | 0 | 0 | 6 | 26 | |||
| Outcomes-Baseline Values | |||||||||
| BMI, kg/m2 | 35.2±7.3 | 33.2±6.2 | 37.2±7.9 | 2.28 | 63 | .03 | |||
| Waist Circumference, inches | 45.0±6.0 | 42.7±5.4 | 47.3±5.8 | 3.33 | 63 | .01 | |||
| Systolic Blood Pressure, mmHg | 133.9±1.7 | 130.2±13.3 | 137.5±24.1 | 1.52 | 63 | .13 | |||
| Diastolic Blood Pressure, mmHg | 85.1±11.1 | 84.0±10.0 | 86.2±12.1 | .78 | 63 | .44 | |||
| Quality of Lifeb | |||||||||
| SF-12 MCS | 29.9±6.9 | 30.1±7.4 | 29.7±6.4 | −.20 | 63 | .84 | |||
| SF-12 PCS | 35.8±8.2 | 34.8±7.7 | 36.8±8.7 | .89 | 63 | .38 | |||
| Functioningc | 18.8±8.7 | 16.7±9.6 | 20.9±7.4 | 1.96 | 63 | .06 | |||
| Symptomsd | |||||||||
| Depressive | 8.8±6.3 | 7.8±6.5 | 9.9±6.0 | 1.40 | 63 | .17 | |||
| Manic | 18.7±12.8 | 16.4±14.3 | 21.0±10.9 | 1.43 | 63 | .16 |
Any current mood stabilizer prescription included Lithium, valproate, carbamazepine, or lamotrigine. Any atypical antipsychotic use included olanzapine, ziprasidone, aripiprazole, quetiapine, clozapine, or ziprazidone
Health-related quality of life (SF-12) includes a mental health (MCS) and physical health component score (PCS). Possible scores range from 0 to 100, with higher scores indicating better health scores. For both summary scores, the population M ± SD is 50 ± 10.
Impaired functioning was assessed using the World Health Organization Disability Assessment Scale, a 12 item measure that assesses the degree of functional impairment experienced over the past month regarding self-care, mobility, cognition, social functioning, and role functioning, with possible scores ranging from 0 to 48 (higher scores indicating worse functioning).
Symptom scores were based on the Internal State Scale, an 8-item assessment of depressive and manic symptoms that are strongly correlated with clinician ratings. For depressive symptoms, possible scores range from 0 to 20. For manic symptoms, possible scores range from 0 to 50, Higher score indicate more severe symptoms.